

## International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature

Evan S. Dellon,<sup>1,a</sup> Nirmala Gonsalves,<sup>2,a</sup> J. Pablo Abonia,<sup>3</sup> Jeffrey A. Alexander,<sup>4</sup> Nicoleta C. Arva,<sup>5</sup> Dan Atkins,<sup>6</sup> Stephen E. Attwood,<sup>7</sup> Marcus K. H. Auth,<sup>8</sup> Dominique D. Bailey,<sup>9,10,11</sup> Luc Biederman,<sup>12</sup> Carine Blanchard,<sup>13</sup> Peter A. Bonis,<sup>14</sup> Paroma Bose,<sup>15</sup> Albert J. Bredenoord,<sup>16</sup> Joy W. Chang,<sup>17</sup> Mirna Chehade,<sup>18</sup> Margaret H. Collins,<sup>19</sup> Carlo Di Lorenzo,<sup>20</sup> Jorge Amil Dias,<sup>21</sup> Ranjan Dohil,<sup>22</sup> Christophe Dupont,<sup>23</sup> Gary W. Falk,<sup>24</sup> Cristina T. Ferreira,<sup>25</sup> Adam T. Fox,<sup>26</sup> Robert M. Genta,<sup>27,28</sup> Thomas Greuter,<sup>12,29</sup> Sandeep K. Gupta,<sup>15</sup> Ikuo Hirano,<sup>2</sup> Girish S. Hiremath,<sup>30</sup> Jennifer L. Horsley-Silva,<sup>31</sup> Shunji Ishihara,<sup>32</sup> Norihisa Ishimura,<sup>32</sup> Elizabeth T. Jensen,<sup>33</sup> Carolina Gutiérrez-Junquera,<sup>34</sup> David A. Katzka,<sup>4</sup> Paneez Houry,<sup>35</sup> Yoshikazu Kinoshita,<sup>36</sup> Kara L. Kliewer,<sup>3</sup> Sibylle Koletzko,<sup>37,38</sup> John Leung,<sup>14</sup> Chris A. Liacouras,<sup>39</sup> Alfredo J. Lucendo,<sup>40</sup> Lisa J. Martin,<sup>41</sup> Emily C. McGowan,<sup>42</sup> Calies Menard-Katcher,<sup>43,44</sup> David C. Metz,<sup>24</sup> Talya L. Miller,<sup>45</sup> Fouad J. Moawad,<sup>46</sup> Amanda B. Muir,<sup>39</sup> Vincent A. Mukkada,<sup>47</sup> Simon Murch,<sup>48</sup> Quan M. Nhu,<sup>46,49,50</sup> Ichiro Nomura,<sup>51</sup> Samuel Nurko,<sup>52</sup> Yoshikazu Ohtsuka,<sup>53</sup> Salvatore Oliva,<sup>54</sup> Rok Orel,<sup>55</sup> Alexandra Papadopoulou,<sup>56</sup> Dhyanes A. Patel,<sup>57</sup> Robert D. Pesek,<sup>58</sup> Kathryn A. Peterson,<sup>59</sup> Hamish Philpott,<sup>60</sup> Philip E. Putnam,<sup>47</sup> Joel E. Richter,<sup>61</sup> Rachel Rosen,<sup>62</sup> Melanie A. Ruffner,<sup>63</sup> Ekaterina Safroneeva,<sup>64</sup> Philipp Schreiner,<sup>12</sup> Alain Schoepfer,<sup>29</sup> Shauna R. Schroeder,<sup>65</sup> Neil Shah,<sup>66,67</sup> Rhonda F. Souza,<sup>68</sup> Stuart J. Spechler,<sup>68</sup> Jonathan M. Spergel,<sup>63</sup> Alex Straumann,<sup>12</sup> Nicholas J. Talley,<sup>69,70,71</sup> Nikhil Thapar,<sup>72,73</sup> Yvan Vandenplas,<sup>74</sup> Rajitha D. Venkatesh,<sup>20</sup> Mario C. Vieira,<sup>75</sup> Ulrike von Arnim,<sup>76</sup> Marjorie M. Walker,<sup>77</sup> Joshua B. Wechsler,<sup>78</sup> Barry K. Wershil,<sup>78</sup> Benjamin L. Wright,<sup>79,80</sup> Yoshiyuki Yamada,<sup>81</sup> Guang-Yu Yang,<sup>82</sup> Noam Zevit,<sup>83</sup> Marc E. Rothenberg,<sup>3</sup> Glenn T. Furuta,<sup>43,44,b</sup> and Seema S. Aceves<sup>84,b</sup>

<sup>1</sup>Center for Esophageal Diseases and Swallowing and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; <sup>2</sup>Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; <sup>3</sup>Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio; <sup>4</sup>Division of Gastroenterology, Mayo Clinic Rochester, Minnesota; <sup>5</sup>Department of Pathology, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois; <sup>6</sup>Section of Pediatric Allergy and Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado; <sup>7</sup>Department of Health Services Research, Durham University, Durham, United Kingdom; <sup>8</sup>Department of Paediatric Gastroenterology, Hepatology and Nutrition, Alder Hey Children's NHS Foundation Trust and University of Liverpool, Liverpool, United Kingdom; <sup>9</sup>Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Columbia University Irving Medical Center, New York, New York; <sup>10</sup>Division of Digestive and Liver Disease, Department of Medicine, Columbia University Irving Medical Center, New York, New York; <sup>11</sup>Columbia Center for Human Development, Columbia University Irving Medical Center, New York, New York; <sup>12</sup>Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland; <sup>13</sup>Department of Gastro-Intestinal Health, Immunology group, Nestlé Institute of Health Sciences, Nestlé Research, Société des Produits Nestlé S.A., Lausanne, Switzerland; <sup>14</sup>Division of Gastroenterology, Tufts University School of Medicine, Boston, Massachusetts; <sup>15</sup>Division of

<sup>a</sup>Authors share co-first authorship. <sup>b</sup>Authors share co-senior authorship.

**Abbreviations used in this paper:** EGID, eosinophilic gastrointestinal disease; EoE, eosinophilic esophagitis; GI, gastrointestinal; ICD, International Classification of Diseases.

© 2022 by the AGA Institute  
1542-3565/\$36.00  
<https://doi.org/10.1016/j.cgh.2022.02.017>

*Pediatric Gastroenterology, Hepatology, and Nutrition, Riley Hospital for Children and Community Health Network, Indiana University School of Medicine, Indianapolis, Indianapolis;* <sup>16</sup>*Department of Gastroenterology, Amsterdam University Medical Center, Amsterdam, the Netherlands;* <sup>17</sup>*Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan;* <sup>18</sup>*Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York;* <sup>19</sup>*Division of Pathology and Laboratory Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio;* <sup>20</sup>*Division of Gastroenterology, Hepatology and Nutrition, Nationwide Children's Hospital, Columbus, Ohio;* <sup>21</sup>*Hospital Lusíadas, Porto, Portugal;* <sup>22</sup>*Division on Pediatric Gastroenterology, Rady's Children's Hospital, University of California, San Diego, San Diego, California;* <sup>23</sup>*Ramsay Group, Marcel Sembat Clinic, Paris Descartes University, Paris, France;* <sup>24</sup>*Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania Philadelphia, Pennsylvania;* <sup>25</sup>*Hospital Santo Antônio, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil;* <sup>26</sup>*Paediatric Allergy, Guy's & St. Thomas' Hospitals NHS Foundation Trust, London, United Kingdom;* <sup>27</sup>*Division of Gastroenterology, Department of Pathology and Medicine, Baylor College of Medicine, Houston, Texas;* <sup>28</sup>*Inform Diagnostics, Irving, Texas;* <sup>29</sup>*Division of Gastroenterology and Hepatology, University Hospital Lausanne, Lausanne, Switzerland;* <sup>30</sup>*Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, Tennessee;* <sup>31</sup>*Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona;* <sup>32</sup>*Department of Internal Medicine II, Shimane University Faculty of Medicine, Shimane, Japan;* <sup>33</sup>*Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina;* <sup>34</sup>*Pediatric Gastroenterology Unit, University Hospital Puerta de Hierro Majadahonda, Autonomous University of Madrid, Majadahonda, Spain;* <sup>35</sup>*Human Eosinophil Section, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, Maryland;* <sup>36</sup>*Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan;* <sup>37</sup>*Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany;* <sup>38</sup>*Department of Pediatrics, Gastroenterology and Nutrition, School of Medicine Collegium Medicum University of Warmia and Mazury, Olsztyn, Poland;* <sup>39</sup>*Center for Pediatric Eosinophilic Disorders, Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;* <sup>40</sup>*Department of Gastroenterology, Hospital General de Tomelloso, Instituto de Investigación Sanitaria Princesa, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Tomelloso, Spain;* <sup>41</sup>*Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, Ohio;* <sup>42</sup>*Division of Allergy and Immunology, University of Virginia School of Medicine, Charlottesville, Virginia;* <sup>43</sup>*Digestive Health Institute, Children's Hospital Colorado, Aurora, Colorado;* <sup>44</sup>*Gastrointestinal Eosinophilic Diseases Program, University of Colorado School of Medicine, Aurora, Colorado;* <sup>45</sup>*Swedish Medical Center, Seattle, Washington;* <sup>46</sup>*Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, California;* <sup>47</sup>*Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio;* <sup>48</sup>*Warwick University Medical School, Coventry, United Kingdom;* <sup>49</sup>*Department of Molecular Medicine, Scripps Research Institute, San Diego, California;* <sup>50</sup>*Division of Allergy and Immunology, University of California, San Diego, La Jolla, California;* <sup>51</sup>*Division of Eosinophilic Gastrointestinal Disorders, Allergy Center, National Center for Child Health and Development, Tokyo, Japan;* <sup>52</sup>*Center for Motility and Functional Gastrointestinal Disorders, Boston Children's Hospital, Boston, Massachusetts;* <sup>53</sup>*Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan;* <sup>54</sup>*Pediatric Digestive Endoscopy, Pediatric Gastroenterology and Liver Unit, Maternal and Child Health Department, University Hospital, University of Rome, Rome, Italy;* <sup>55</sup>*University Children's Hospital Ljubljana, Faculty of Medicine, University of Ljubljana, Slovenia;* <sup>56</sup>*Division of Gastroenterology and Hepatology, Children's Hospital Agia Sofia, First Department of Pediatrics, University of Athens, Athens, Greece;* <sup>57</sup>*Center for Esophageal Disorders, Vanderbilt University Medical Center, Nashville, Tennessee;* <sup>58</sup>*Division of Allergy and Immunology, Department of Pediatrics, Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas;* <sup>59</sup>*Division of Gastroenterology, University of Utah, Salt Lake City, Utah;* <sup>60</sup>*Department of Gastroenterology, Lyell McEwin Hospital, University of Adelaide, Adelaide, Australia;* <sup>61</sup>*Morsani College of Medicine, University of South Florida, Tampa, Florida;* <sup>62</sup>*Aerodigestive Center, Boston Children's Hospital, Boston, Massachusetts;* <sup>63</sup>*Division of Allergy and Immunology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;* <sup>64</sup>*Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland;* <sup>65</sup>*Division of Gastroenterology, Hepatology, and Nutrition, Phoenix Children's Hospital, Phoenix, Arizona;* <sup>66</sup>*Portland Hospital, London, United Kingdom;* <sup>67</sup>*Reckitt Healthcare, Slough, United Kingdom;* <sup>68</sup>*Division of Gastroenterology and Center for Esophageal Diseases, Baylor Scott & White Center for Esophageal Research, Baylor University Medical Center, Baylor Scott & White Research Institute, Dallas, Texas;* <sup>69</sup>*School of Medicine and Public Health, University of Newcastle, Newcastle, Australia;* <sup>70</sup>*National Health and Medical Research Council Centre of Research Excellence on Digestive Health, Newcastle, Australia;* <sup>71</sup>*Hunter Medical Research Institute, New Lambton Heights, Australia;* <sup>72</sup>*Department of Gastroenterology, Hepatology and Liver Transplant, Queensland Children's Hospital, School of Medicine, University of Queensland, Brisbane, Australia;* <sup>73</sup>*Woolworths Centre for Child Nutrition Research, Queensland University of Technology, Brisbane, Australia;* <sup>74</sup>*KidZ Health Castle, Vrije Universiteit Brussel, Brussels, Belgium;* <sup>75</sup>*Center for Pediatric Gastroenterology, Hospital Pequeno Príncipe, Curitiba, Brazil;* <sup>76</sup>*Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Magdeburg, Magdeburg, Germany;* <sup>77</sup>*Department of Pathology, College of Health, Medicine and Wellbeing, Faculty of Health and Medicine, University of Newcastle Callaghan, Australia;* <sup>78</sup>*Division of Gastroenterology, Hepatology, and Nutrition, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois;* <sup>79</sup>*Division of Allergy, Asthma, and Clinical Immunology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona;* <sup>80</sup>*Section of Allergy and Immunology, Division of Pulmonology, Phoenix Children's Hospital, Phoenix, Arizona;* <sup>81</sup>*Department of Pediatrics, Tokai University School of Medicine, Kanagawa, Japan;* <sup>82</sup>*Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois;* <sup>83</sup>*Institute of Gastroenterology, Hepatology, and Nutrition, Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine, Tel-Aviv University, Petah-Tikva, Israel; and* <sup>84</sup>*Division of Allergy, Immunology, and Rheumatology, Departments of Pediatrics and Medicine, Rady Children's Hospital, University of California San Diego, San Diego, California*

- BACKGROUND & AIMS:** Substantial heterogeneity in terminology used for eosinophilic gastrointestinal diseases (EGIDs), particularly the catchall term “eosinophilic gastroenteritis,” limits clinical and research advances. We aimed to achieve an international consensus for standardized EGID nomenclature.
- METHODS:** This consensus process utilized Delphi methodology. An initial naming framework was proposed and refined in iterative fashion, then assessed in a first round of Delphi voting. Results were discussed in 2 consensus meetings, and the framework was updated and reassessed in a second Delphi vote, with a 70% threshold set for agreement.
- RESULTS:** Of 91 experts participating, 85 (93%) completed the first and 82 (90%) completed the second Delphi surveys. Consensus was reached on all but 2 statements. “EGID” was the preferred umbrella term for disorders of gastrointestinal (GI) tract eosinophilic inflammation in the absence of secondary causes (100% agreement). Involved GI tract segments will be named specifically and use an “Eo” abbreviation convention: eosinophilic gastritis (now abbreviated EoG), eosinophilic enteritis (EoN), and eosinophilic colitis (EoC). The term “eosinophilic gastroenteritis” is no longer preferred as the overall name (96% agreement). When >2 GI tract areas are involved, the name should reflect all of the involved areas.
- CONCLUSIONS:** This international process resulted in consensus for updated EGID nomenclature for both clinical and research use. EGID will be the umbrella term, rather than “eosinophilic gastroenteritis,” and specific naming conventions by location of GI tract involvement are recommended. As more data are developed, this framework can be updated to reflect best practices and the underlying science.

*Keywords:* Eosinophilic Gastrointestinal Disease; Eosinophilic Gastroenteritis; Delphi; Nomenclature; Classification.

Eosinophilic gastrointestinal diseases (EGIDs) are chronic, immune-mediated disorders characterized clinically by gastrointestinal (GI) symptoms and histologically by a pathologic increase in eosinophil-predominant inflammation in specific regions of the GI tract, in the absence of secondary causes of eosinophilia.<sup>1,2</sup> The best known of these is eosinophilic esophagitis (EoE),<sup>3-5</sup> but the non-EoE EGIDs are now the subject of intensive study due to increased clinical awareness of these conditions. Non-EoE EGIDs can involve the stomach, small bowel, and colon, either individually or in any combination of segments, and can also vary in the depth of involvement of the GI tract layers. Recent investigations have focused on understanding the clinical presentation, epidemiology, natural history, pathogenesis, and effective treatments.<sup>6-22</sup>

At present, no guidelines exist for diagnosis or treatment of the non-EoE EGIDs, but efforts are actively underway to develop these. As this guideline process started, there was substantial confusion related to EGID terminology, particularly pertaining to the catchall term “eosinophilic gastroenteritis.” There has been variable use of this term in both clinical settings and research studies, with ambiguity and heterogeneity in its definition.<sup>8,13,23-26</sup> Over many years, the phrase “eosinophilic gastroenteritis” has been used to indicate different sites of involvement including stomach alone, small bowel alone, stomach and small bowel, stomach or small bowel, or involvement anywhere along the GI tract.

This nonstandardized use of nomenclature highlighted a need for a common language for non-EoE eosinophilic GI disease names, not only for clinical practice, but also for the consistent data collection required for research to continue to advance the field. Therefore, the aim of this effort was to achieve an international consensus for consistent EGID nomenclature.

## Materials and Methods

### *Overview and Principles*

This was an iterative and inclusive process with formalized feedback utilizing standard Delphi methods.<sup>27</sup> A 4-person steering group (E.S.D., N.G., G.T.F., S.S.A.) first reviewed the literature and developed several potential nomenclature systems, which were then shared and refined amongst an expanded focus group. Additional feedback was solicited from members of the Consortium of Eosinophilic Gastrointestinal Disease Researchers,<sup>28</sup> as well as from members outside of this group. Based on the feedback, an initial nomenclature framework was proposed.

A number of principles guided the first part of the development process. First, when terminology was not ambiguous, the goal was to retain as much of the existing nomenclature as possible. This was to minimize confusion among clinicians, researchers, and patients and to retain existing International Classification of Diseases

(ICD) codes. The second was to strongly consider the removal of the term “eosinophilic gastroenteritis” from the framework, given the variability in its use. The third was to create a basic level of nomenclature that would be intuitive and useful for clinical practice. The fourth was to include a second tier of more detailed nomenclature that could be utilized for research purposes, with a focus on granularity in naming since terms can always be combined as future information is gained but cannot be split. The fifth was to solicit and receive feedback during the process from stakeholders, including patient advocacy groups, regulatory authorities, researchers, and clinicians. The sixth was to move forward with the recognition that the framework developed would be a starting point and expected to change in the future, as informed by emerging data.

### *Delphi 1*

After the framework had been established, the next step was the first Delphi round of questions. An international and multidisciplinary group of adult and pediatric clinicians and researchers with experience in EGIDs, esophageal disorders, immunology, functional disorders, and other areas, spanning specialties of gastroenterology, allergy, pathology, basic and translational science, and epidemiology, was recruited to complete a 42-question online survey distributed using the Qualtrics platform. Questions focused on use of the term “eosinophilic gastroenteritis” and other possible nomenclature options. A figure of the framework was presented at the beginning of the survey, and respondents were asked to rate their level of agreement to a series of statements on a 5-point scale: strongly disagree, disagree, neither agree nor disagree, agree, and strongly agree. Free text comments were also allowed. Summary statistics for the responses were calculated and a level of agreement of 70% (the sum of agree and strongly agree) was set a priori.

### *Consensus Meetings*

After the initial Delphi responses were analyzed, all respondents participated in 1 of 2 scheduled consensus meetings in May 2021. Two meetings were scheduled to accommodate the large number of participants who were located on 5 continents and because an in-person meeting was not possible due to the COVID-19 (coronavirus disease 2019) pandemic. These meetings were approached in identical fashion and conducted via a video conferencing platform with a chat interface. Data were reviewed and then the discussion focused on areas of disagreement, proposed new terminology, the role of the term “eosinophilic gastroenteritis,” and how to approach naming eosinophilic disease in the small bowel. Active participation was sought from all participants, and comments in the chat were recorded and reviewed. In addition, preliminary results were shared with

## **What You Need to Know**

### **Background**

There is substantial variability in terminology for naming eosinophilic gastrointestinal diseases (EGIDs), and there has been heterogeneous use of the catchall term “eosinophilic gastroenteritis” in both clinical settings and research studies.

### **Findings**

This Delphi process, in which 91 experts participated, resulted in international consensus for a new nomenclature framework for EGIDs. “EGID” should now be used as the umbrella term for diseases of the gastrointestinal tract with pathologic eosinophilic infiltration in the absence of secondary causes. Involvement of individual gastrointestinal tract locations should be named specifically, and an “Eo” abbreviation convention should be used: EoG for eosinophilic gastritis, EoN for eosinophilic enteritis, and EoC for eosinophilic colitis; eosinophilic esophagitis remains EoE. The term “eosinophilic gastroenteritis” will no longer be used as an umbrella name.

### **Implications for patient care**

Patients, clinicians, and researchers should use this new nomenclature. The first tier of nomenclature can be used routinely in clinical practice, while the second tier can be used clinically and in research. This more specific naming paradigm will allow more precise clinical phenotyping, which will inform guideline development and future research directions.

stakeholders, including patient advocacy groups, industry representatives, and representatives from the Food and Drug Administration during the GREAT VI (Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI) Workshop on EGIDs beyond EoE (July 2021).<sup>29</sup>

### *Delphi 2*

All feedback from the consensus meetings and additional comments received were incorporated into an updated framework. This was again done in an iterative fashion, first with the steering group and then with the extended focus group members. After this, a second round of Delphi questions was developed and distributed to the same large international group that completed the first Delphi round. There were 29 questions, again distributed in an online survey, focusing on the updated framework. Respondents were asked only whether they agreed or disagreed with each of the statements (2-point scale without a neutral option). Summary statistics for

the responses were calculated and a level of agreement of 70% was set a priori.

## Results

### *Demographics and Variability in Terminology Use*

Of the 91 experts invited to participate, 85 (93%) completed the first Delphi survey. There were 32 (38%) women and 53 (62%) men, with a median time in practice of 21 (interquartile range, 9–30) years. Nearly half (48%) of participants saw children or adolescents in practice, 12% saw adolescents and adults, 18% saw adults only, 14% saw patients of all ages, and 8% did not see patients. Practice settings were largely academic or university based (91%), and 53% saw 3 or more non-EoE EGID patients per month (Table 1).

To gauge how participants currently viewed terminology, they were asked the question: “When I use the term ‘eosinophilic gastroenteritis,’ I mean to indicate that the disease involves (please check all of the following that apply).” There was no majority consensus answer to this question. The 2 most common answers were “stomach AND small bowel,” reported by 36 (42%), and “any location along the GI tract,” reported by 11 (13%). However, there was substantial variability in responses, with more than 13 other definitions for “eosinophilic gastroenteritis” provided, representing a range of different locations along the GI tract (Figure 1).

### *Delphi 1 Results and Consensus Meetings*

Full data on the initial Delphi results are presented in [Supplementary Table 1](#). There was strong agreement in the first round of the Delphi process and in the consensus meetings that the umbrella term for disorders of GI tract eosinophilic inflammation in the absence of secondary causes should be “eosinophilic gastrointestinal disease” (96% either agreed or strongly agreed), and that when an EGID involves only the esophagus, the name should remain EoE (97% either agreed or strongly agreed). There was also strong agreement that when an EGID involves only the stomach or colon, the name should be eosinophilic gastritis or eosinophilic colitis, respectively (95% agreed or strongly agreed for both).

There was no consensus on whether the term “eosinophilic gastroenteritis” should be removed from an EGID nomenclature system (10% strongly agree, 25% agree, 25% neutral, 30% disagree, 11% strongly disagree). In the initial survey comments and in the discussions during the meetings, reasons for removing the term were related to variability in use, unclear definition or meaning, and limitations related to an ability to know whether the stomach or bowel (or both) were involved. Reasons for retaining the term included its historical nature and use, its ongoing use in current

**Table 1.** Characteristics of EGID Nomenclature Delphi Process (n = 85)


Sex	
Female	32 (38)
Male	53 (62)
Time in practice, y	21 (9–30, 1–44)
Specialty	
Gastroenterology	60 (70)
Allergy/immunology	15 (18)
Pathology	5 (6)
Other	5 (6)
Type of patients seen	
Children and/or adolescents	41 (48)
Adolescents and adults	10 (12)
Adults	15 (18)
All ages	12 (14)
Do not see patients	7 (8)
Practice setting	
Academic/university	77 (91)
Private/community practice	4 (5)
Not practicing	3 (3)
Industry	1 (1)
Location	
North America	49 (58)
South America	2 (2)
Europe	24 (28)
Asia	6 (7)
Australia	4 (5)
Non-EoE EGID patients seen per month	
<3	33 (47)
3–5	13 (19)
5–10	9 (13)
>10	15 (21)

Values are n (%) or median (interquartile range, range).

EGID, eosinophilic gastrointestinal disease; EoE, eosinophilic esophagitis.

research studies and protocols, and the need to potentially redefine the term (stomach and small bowel involvement only) but not use it as an umbrella term any longer. This last option carried weight and began to generate consensus.

During the Delphi 1 process, consensus was also not reached on what to name small bowel involvement alone, and there was 61% agreement, 19% neutral, and 21% disagreement with the term “eosinophilic pan-enteritis.” In the comments and discussion, there was debate as to whether specifying all parts of small bowel involvement (eg, duodenum vs jejunum vs ileum) was necessary or even practical, given that assessment of the mid or distal small bowel may not be clinically indicated and performing deep enteroscopy or video capsule endoscopy may not be possible at all centers. Nevertheless, there was consensus on naming of eosinophilic duodenitis (75% strongly agreeing or agreeing, 21% neutral, 11% disagreeing). There was also debate about whether to include depth of wall layer involvement, EGID complications, or uninvestigated areas of the GI tract in the nomenclature framework ([Supplementary Table 1](#)).



**Figure 1.** Variability in responses for how the term “eosinophilic gastroenteritis” is used to reflect different areas of involvement in the GI tract.

### Delphi 2 Results

There were 82 (90%) responses from the 91 participants for the Delphi round 2 survey, and overall consensus was reached on all statements from the updated framework (based on input from the Delphi round 1 and consensus meetings) with the exception of 2 statements (Table 2). There was universal (100%) consensus on using the umbrella term EGID for disorders of GI tract eosinophilic inflammation in the absence of secondary causes, as well as the names eosinophilic gastritis and eosinophilic colitis. There was 95% agreement to naming an EGID involving the small intestine as “eosinophilic enteritis” and 94% agreement that it was desirable, but not required, to name specific locations of small bowel involvement, when known. There was also consensus for naming the individual segments of the small bowel (ie, eosinophilic duodenitis).

For abbreviations, agreement was reached to have an “Eo” naming convention, consistent with what is already used for EoE. Therefore eosinophilic gastritis would be EoG, eosinophilic duodenitis would be EoD, and eosinophilic colitis would be EoC. There was debate around how to abbreviate small bowel involvement, but ultimately 79% agreed with “EoN” (indicating “Eosinophilic eNteritis”).

During the Delphi 2 process, the term “eosinophilic gastroenteritis” was de-emphasized and will no longer be the preferred umbrella term for EGIDs (96% agreement). When used, it should only be used when both the

stomach and the small bowel are involved (83% agreement). There was also consensus that when more than 2 GI tract areas (outside of the esophagus) are involved, the name should reflect the involved areas (96% agreement) (Table 2).

The first topic where consensus was not reached related to overlapping esophageal involvement. Only 61% agreed with the statement that for EGIDs that involve the stomach or small bowel or the colon, and also the esophagus, the term to indicate this should be “with esophageal involvement.” The second topic was related to whether areas of the GI tract that were not investigated or had unknown involvement should be specified in the nomenclature framework (65% agreement).

### Discussion

Research related to EGIDs is rapidly advancing. However, the field of non-EoE EGIDs is in a position similar to where EoE was in the early 2000s, without diagnostic or management guidelines, and with a literature that can be difficult to interpret based on different disease definitions and terminologies used.<sup>30</sup> In particular, the term “eosinophilic gastroenteritis” has been confusing, as it has often been used to represent any type of eosinophilic GI infiltration, not just stomach and small bowel. In that context, our large, international, and multidisciplinary group came together to conduct a Delphi process to standardize EGID nomenclature. This

**Table 2.** Agreement Data From Round 2 of the Delphi Voting Process (n = 82)

	Agree	Disagree
The umbrella term for disorders of GI tract eosinophilic inflammation in the absence of secondary causes should be “eosinophilic gastrointestinal disease” (EGID)	82 (100)	0 (0)
When an EGID involves the esophagus, the name should remain “eosinophilic esophagitis” (EoE)	80 (98)	2 (2)
When an EGID involves the stomach, the name should be “eosinophilic gastritis”	82 (100)	0 (0)
When an EGID involves the colon, the name should be “eosinophilic colitis”	82 (100)	0 (0)
When an EGID involves the small intestine, the general name should be “eosinophilic enteritis”	78 (95)	4 (5)
For the abbreviation for eosinophilic gastritis, should it be “EG” or “EoG”?	EoG: 72 (88)	EG: 10 (12)
For the abbreviation for eosinophilic colitis, should it be “EC” or “EoC”?	EoC: 72 (88)	EC: 10 (12)
For the abbreviation for eosinophilic enteritis, should it be “EEN” or “EoN”	EoN 65 (79)	EEN: 17 (21)
It is desirable, but not required, to name specific locations of small bowel involvement, if these are known.	77 (94)	5 (6)
When an EGID involves the duodenum, the name should be “eosinophilic duodenitis”	76 (93)	6 (7)
The abbreviation for eosinophilic duodenitis should be “EoD”	75 (91)	7 (9)
When an EGID involves the jejunum, the name should be “eosinophilic jejunitis”	76 (94)	6 (7)
The abbreviation for eosinophilic jejunitis should be “EoJ”	73 (89)	9 (11)
When an EGID involves the ileum, the name should be “eosinophilic ileitis”	77 (94)	5 (6)
The abbreviation for eosinophilic ileitis should be “EoI”	74 (90)	8 (10)
The term “eosinophilic gastroenteritis” should be redefined and <u>only</u> used to indicate gastric <u>AND</u> small bowel involvement	68 (83)	14 (17)
The term “eosinophilic gastroenteritis” will no longer be used as the umbrella term for EGIDs	79 (96)	3 (4)
For EGIDs that involve the stomach and/or small bowel and/or the colon, and ALSO the esophagus, the term to indicate this should be “with esophageal involvement”	50 (61)	32 (39)
When more than 2 GI tract areas (outside of the esophagus) are involved, the name should reflect the involved areas (ie stomach + duodenum = eosinophilic gastritis and duodenitis; duodenum + colon = eosinophilic duodenitis and colitis; etc)	79 (96)	3 (4)
The GI wall layer of involvement (or if this is unknown) should be noted	65 (79)	17 (21)
Complications of EGIDs (for example, protein-losing enteropathy, ascites, or numerous others) should be noted	67 (82)	15 (18)
Any areas of the GI tract that are not investigated or have unknown involvement should be noted	53 (65)	29 (35)


Values are n (%).

EC/EoC, eosinophilic colitis; EEN/EoN, eosinophilic enteritis; EG/EoG, eosinophilic gastritis; EGID, eosinophilic gastrointestinal disease; EoE, eosinophilic esophagitis; EoD, eosinophilic duodenitis; EoI, eosinophilic ileitis; EoJ, eosinophilic jejunitis; GI, gastrointestinal.

step, while seemingly rudimentary, was essential to inform the guideline efforts that are now underway.

The results from this iterative and collaborative process showed that even amongst this group of experts, the term “eosinophilic gastroenteritis” was variably used, and agreement to redefine and deemphasize this term was reached. The new framework for EGID nomenclature that resulted from this Delphi process is presented in [Figure 2](#). “EGID” should now be used as the umbrella term for diseases of the GI tract with pathologic eosinophilic infiltration in the absence of secondary causes. In the first tier of nomenclature that will be used routinely in clinical practice, esophageal involvement alone remains EoE. Any other location of involvement can be termed a non-EoE EGID. Naming is then by location of

inflammation, with the stomach being termed eosinophilic gastritis (EoG), small bowel termed eosinophilic enteritis (EoN), and colon termed eosinophilic colitis (EoC). In the second tier of nomenclature, which can be used clinically but should be used for research, there is an emphasis on further granularity with naming, in particular when there is small bowel involvement and when there are multiple nonesophageal locations involved. For example, stomach and small bowel involvement should be termed eosinophilic gastritis and enteritis, and stomach and duodenal involvement should be termed eosinophilic gastritis and duodenitis. Because there was not consensus when the esophagus is also involved, this can either be termed “with esophageal involvement” or “EoE,” but with the understanding that



**Figure 2.** Consensus nomenclature framework for EGIDs. Note that for naming multiple involved GI segments, representative examples are provided, but not all possible combinations are listed.

by current diagnostic criteria, EoE is isolated to the esophagus.<sup>3</sup> Additionally, the GI wall layer of involvement, if known, should be noted, along with complications that may be present. These can include protein-losing enteropathy, ascites, anemia, strictures, ulcers, perforations, or others.

While this process yielded nearly universal agreement on almost every facet of EGID nomenclature, there were exceptions that were vigorously debated, mostly concerning how to address patients with multiple areas of the GI tract involved. EGIDs with multiple areas of involvement are challenging since there are few data addressing whether there is a disease spectrum with a shared pathogenesis or not. In this context, many participants felt it was important to identify a “primary” location of the EGID named after taking into account the predominant symptoms, endoscopic features, and complications, not simply just the histologic findings. Therefore, a patient with gastric, small bowel, and colonic involvement, but with protein-losing enteropathy, malabsorption, diarrhea, and small bowel strictures, would be classified primarily as EoN. If this patient instead had anorexia, weight loss, abdominal pain, and gastric ulceration with pyloric stenosis, the classification would primarily be EoG. A similar issue was raised when the esophagus was involved. Some patients with esophageal and gastric involvement, for example, may have primarily “EoE-like” symptoms and findings (with dysphagia, esophageal stricturing, and need for dilation) but also have superimposed gastric symptoms, while some may have minimal dysphagia and heartburn, but

abdominal pain and gastric ulceration predominate. The former patient might be classified as “EoE and EoG,” while the latter may be better termed “EoG with esophageal involvement.” However, it was acknowledged that this is likely a part of the nomenclature framework that will evolve in the future as pertinent data become available. Another major area of emphasis was that the clinical picture, and not the nomenclature, should drive the clinically indicated evaluation and treatment. Therefore, while upper endoscopy is typically indicated in most cases of chronic GI symptoms, colonoscopy and additional deep enteroscopy or imaging techniques are not required in all patients. In particular, there was a strong desire to keep testing to what is clinically relevant and not over-investigate symptoms once a diagnosis is made, particularly in children. There is no need to “stage” entire GI tract or investigate areas of the bowel that are not responsible for symptoms. Further discussion of this topic, however, was beyond the scope of the nomenclature effort and will be more thoroughly addressed in diagnostic guidelines which are under development.

There are several limitations to acknowledge with the current consensus approach. First, the participants tended to be from academic or university settings, and therefore were not representative of all practitioners. However, an overriding goal of this process was to have a simplified approach in a “first tier” of nomenclature than can be adopted by all clinicians, and this was accomplished with the EGID umbrella term, the EoE vs non-EoE EGID designation, and the naming conventions for the gastric, small bowel, and colonic locations. We added a

more complex “second tier” to be used in a research setting, or when a clinician would like to provide more details and granularity for better patient characterization and follow-up. This framework is analogous to a general gastroenterologist using the term ileocolonic Crohn’s in a patient with inflammatory bowel disease, whereas a researcher would use the full Montreal classification system.<sup>31</sup> Second, this nomenclature is for luminal GI disorders, so it does not currently apply to eosinophilic gallbladder, liver, or pancreatic diseases. Last, the small bowel nomenclature remains challenging. It may be either too general (enteritis), too specific (jejunitis), or limited (duodenitis, without noting additional small bowel extent). However, the current terms, designations, and conventions for naming multiple segments provides a reasonable and standardized starting point for the field.

A benefit of the EGID nomenclature process is that these identified limitations suggest clear and immediate directions for research. The debate about whether to use “esophageal involvement” or “EoE” can be addressed when molecular and pathogenic data are compared between patients with only esophageal involvement and patients with esophageal and “lower” involvement. If molecular profiles pathogenic mechanisms are the same in each case, then names can be the same; if the features, treatment, or prognosis are distinct, then the naming convention can also be different. Similarly, it remains to be investigated whether patients with gastric and small bowel involvement are the same as those with gastric alone or small bowel alone, though some data on clinical presentation and treatment response related to this question are beginning to emerge.<sup>12,20–22</sup> Naming precision will also be helpful for assessing and contextualizing therapeutic response. A final aspect to consider is how this nomenclature will ultimately mesh with the current ICD coding system. Current EGID ICD-10 codes include eosinophilic esophagitis (K20.0), eosinophilic gastritis or gastroenteritis (K52.81), and eosinophilic colitis (K52.82). If ongoing research supports the currently proposed updated nomenclature framework, then ICD coding will likely need to be updated to reflect this as well.

In conclusion, this international consensus process has resulted in updated EGID nomenclature that should be used for both clinical and research purposes. EGID will be the umbrella term for diseases of eosinophilic infiltration of the GI tract, and the term “eosinophilic gastroenteritis” will no longer be used in this role, and will ideally be replaced in favor of more specific naming conventions. If the term “eosinophilic gastroenteritis” is used, it should only be for the times that both stomach and small bowel are involved. The iterative and collaborative process led to agreement on nearly all aspects of the proposed nomenclature framework, and has identified future research directions. It is expected that as more data are collected, the nomenclature will again be updated to reflect best practices and the underlying pathogenesis of these disorders.

## Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Clinical Gastroenterology and Hepatology* at [www.cghjournal.org](http://www.cghjournal.org), and at <https://doi.org/10.1016/j.cgh.2022.02.017>.

## References

1. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). *J Allergy Clin Immunol* 2004;113:11–28; quiz 29.
2. Gonsalves N. Eosinophilic gastrointestinal disorders. *Clin Rev Allergy Immunol* 2019;57:272–285.
3. Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. *Gastroenterology* 2018;155:1022–1033.e10.
4. Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. *Gastroenterology* 2020;158:1776–1786.
5. Rank MA, Sharaf RN, Furuta GT, et al. Technical review on the management of eosinophilic esophagitis: a report from the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. *Gastroenterology* 2020;158:1789–1810.e15.
6. Pesek RD, Reed CC, Muir AB, et al. Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic Gastritis, Gastroenteritis, and Colitis Based on 10-Year Data Across a Multicenter Consortium. *Am J Gastroenterol* 2019;114:984–994.
7. Pesek RD, Reed CC, Collins MH, et al. Association between endoscopic and histologic findings in a multicenter retrospective cohort of patients with non-esophageal eosinophilic gastrointestinal disorders. *Dig Dis Sci* 2020;65:2024–2035.
8. Reed C, Woosley JT, Dellon ES. Clinical characteristics, treatment outcomes, and resource utilization in children and adults with eosinophilic gastroenteritis. *Dig Liver Dis* 2015;47:197–201.
9. Ko HM, Morotti RA, Yershov O, et al. Eosinophilic gastritis in children: clinicopathological correlation, disease course, and response to therapy. *Am J Gastroenterol* 2014;109:1277–1285.
10. Chang JY, Choung RS, Lee RM, et al. A shift in the clinical spectrum of eosinophilic gastroenteritis toward the mucosal disease type. *Clin Gastroenterol Hepatol* 2010;8:669–675, quiz e88.
11. Grandinetti T, Biedermann L, Bussmann C, et al. Eosinophilic gastroenteritis: clinical manifestation, natural course, and evaluation of treatment with corticosteroids and vedolizumab. *Dig Dis Sci* 2019;64:2231–2241.
12. Yamamoto M, Nagashima S, Yamada Y, et al. Comparison of nonesophageal eosinophilic gastrointestinal disorders with eosinophilic esophagitis: a nationwide survey. *J Allergy Clin Immunol Pract* 2021;9:3339–3349.e8.
13. Jensen ET, Martin CF, Kappelman MD, et al. Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: estimates from a national administrative database. *J Pediatr Gastroenterol Nutr* 2016;62:36–42.
14. Hiremath G, Kodroff E, Strobel MJ, et al. Individuals affected by eosinophilic gastrointestinal disorders have complex unmet needs and frequently experience unique barriers to care. *Clin Res Hepatol Gastroenterol* 2018;42:483–493.

15. Jensen ET, Aceves SS, Bonis PA, et al. High patient disease burden in a cross-sectional, multicenter contact registry study of eosinophilic gastrointestinal diseases. *J Pediatr Gastroenterol Nutr* 2020;71:524–529.
16. Chehade M, Kamboj AP, Atkins D, et al. Diagnostic delay in patients with eosinophilic gastritis and/or duodenitis: a population-based study. *J Allergy Clin Immunol Pract* 2021; 9:2050–2059.e20.
17. Caldwell JM, Collins MH, Stucke EM, et al. Histologic eosinophilic gastritis is a systemic disorder associated with blood and extra-gastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. *J Allergy Clin Immunol* 2014;134:1114–1124.
18. Shoda T, Wen T, Caldwell JM, et al. Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: multi-site study. *J Allergy Clin Immunol* 2020; 145:255–269.
19. Reed CC, Genta RM, Youngblood BA, et al. Mast cell and eosinophil counts in gastric and duodenal biopsy specimens from patients with and without eosinophilic gastroenteritis. *Clin Gastroenterol Hepatol* 2021;19:2102–2111.
20. Gonsalves N, Doerfler B, Zalewski A, et al. Results from the ELEMENT study: prospective study of elemental diet in eosinophilic gastroenteritis nutrition trial. *Gastroenterology* 2020; 158(Suppl 1):S-43 (AB 229).
21. Dellon ES, Peterson KA, Murray JA, et al. Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis. *N Engl J Med* 2020; 383:1624–1634.
22. Dellon ES, Gonsalves N, Rothenberg ME, et al. Determination of biopsy yield that optimally detects eosinophilic gastritis and/or duodenitis in a randomized trial of lirentelimab. *Clin Gastroenterol Hepatol* 2022;20:535–545.e15.
23. Dellon ES, Collins MH, Bonis PA, et al. Substantial variability in biopsy practice patterns among gastroenterologists for suspected eosinophilic gastrointestinal disorders. *Clin Gastroenterol Hepatol* 2016;14:1842–1844.
24. Licari A, Votto M, Scudeller L, et al. Epidemiology of non-esophageal eosinophilic gastrointestinal diseases in symptomatic patients: a systematic review and meta-analysis. *J Allergy Clin Immunol Pract* 2020;8:1994–2003.e2.
25. Ishihara S, Kinoshita Y, Schoepfer A. Eosinophilic esophagitis, eosinophilic gastroenteritis, and eosinophilic colitis: common mechanisms and differences between East and West. *Inflamm Intest Dis* 2016;1:63–69.
26. Lucendo AJ, Serrano-Montalban B, Arias A, et al. Efficacy of dietary treatment for inducing disease remission in eosinophilic gastroenteritis. *J Pediatr Gastroenterol Nutr* 2015;61:56–64.
27. Hohmann E, Brand JC, Rossi MJ, et al. Expert opinion is necessary: Delphi Panel methodology facilitates a scientific approach to consensus. *Arthroscopy* 2018;34:349–351.
28. Gupta SK, Falk GW, Aceves SS, et al. Consortium of Eosinophilic Gastrointestinal Disease Researchers: advancing the field of eosinophilic GI disorders through collaboration. *Gastroenterology* 2019;156:838–842.
29. Rothenberg ME, Hottinger SKB, Gonsalves N, et al. Impressions and aspirations from the FDA GREAT VI Workshop on eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis and perspectives for progress in the field. *J Allergy Clin Immunol* 2021 Dec 22 [E-pub ahead of print].
30. Dellon ES, Aderoju A, Woosley JT, et al. Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. *Am J Gastroenterol* 2007;102:2300–2313.
31. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 2006;55:749–753.

---

#### Reprint requests

Address requests for reprints to: Evan S. Dellon MD, MPH, CB#7080, Bioinformatics Building, 130 Mason Farm Road, UNC-CH, Chapel Hill, North Carolina 27599-7080. e-mail: [edellon@med.unc.edu](mailto:edellon@med.unc.edu); fax: (919) 843-2508.

#### Acknowledgments

The authors gratefully acknowledge the input and review from the following patient advocacy groups and their representatives: the American Partnership for Eosinophilic Disorders (Mary Jo Strobel), AusEE (Sarah Gray), the Campaign Urging Research for Eosinophilic Disease (Ellyn Kodroff), the Eosinophilic Family Coalition (Amy Zicarelli), and EosNetwork (Amanda Cordell). They also thank Rhona Jackson for her administrative assistance in coordinating this process and manuscript submission.

#### Conflicts of interest

These authors disclose the following: Evan S. Dellon has received research funding from Adare/Ellodi, Allakos, Arena, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, and Shire/Takeda; served as a consultant for Abbott, AbbVie, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, InveniAI, Landos, LucidDx, Morphic, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Roberts/Alimentiv, Salix, Sanofi, Shire/Takeda, and Target RWE; and received educational grant support from Allakos, Banner, and Holoclara. Nirmala Gonsalves has served as a consultant for Allakos, Astra-Zeneca, Knopp, AbbVie, Regeneron-Sanofi, and Nutricia; served on the speakers bureau for Takeda; received royalties from UptoDate, and Abonia; and served as a consultant for Takeda. Jeffrey A. Alexander has served as a consultant for Lucid Technologies; has received research funding from Shire/Takeda, Adair, and Regeneron; and owns financial interest in Meritage Pharmacia. Stephen E. Attwood has served as a consultant for Dr. Falk Pharma, Eso-Cap, AstraZeneca, and Regeneron/Sanofi; and received speaker fees from Medtronic, Vifor Pharma, and Rafa Pharma. Marcus K.H. Auth has received investigator fees from Dr. Falk Pharma; received educational grants from Nutricia, Abbott, and Mead Johnson; and received speaker fees from AbbVie; and served on the advisory board for EosNetwork. Luc Biederman has received consulting fees and/or speaker fees and/or research grants from Dr. Falk Pharma, Vifor AG, Esocap AG, Sanofi-Aventis AG, and Calypso Biotech SA. Carine Blanchard Employed by Soci  t   des Produits Nestl   S.A. Albert J. Bredenoord has received research funding from Thelial, Nutricia, Bayer, Norgine, and SST; and speaker and/or consultancy fees from Thelial, AstraZeneca, Celgene, Regeneron/Sanofi, Arena, Dr. Falk Pharma, Esocap, Calypso Biotech, and Alimentiv. Joy W. Chang has served on the advisory board for Takeda, Sanofi Genzyme, and Lucid Diagnostics. Mirna Chehade has served as a consultant for Regeneron, Allakos, Adare/Ellodi, Shire/Takeda, AstraZeneca, Sanofi, Bristol Myers Squibb, and Phathom; and received research funding from Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, and Danone. Margaret H. Collins has served as a consultant for Alimentiv (formerly Roberts Clinical Trials, Inc), Allakos, Arena, AstraZeneca, Calypso, Esocap, GlaxoSmithKline, Receptos/Celgene/BMC, Regeneron, and Takeda; and received research funds from AstraZeneca, Receptos/Celgene/BMC, Regeneron, and Takeda. Jorge Amil Dias has received honoraria for lectures from Takeda, Ferrer, and Danone; and consulting fees from AdacYTE. Ranjan Dohil's institution, the University of California San Diego, has a financial interest in Shire Pharmaceuticals, the company to which oral viscous budesonide is licensed; he and the University of California San Diego may financially benefit from this interest if the company is successful in developing and marketing its own product, and the terms of the arrangement have been reviewed by the University of California San Diego in accordance with its conflict-of-interest policies. Christophe Dupont has served as a consultant for SAB Abbott, Biostime, Danone, Nestl  , and Sodilac. Gary W. Falk has received consulting fees from Shire/Takeda, Ellodi, Celgene/BMS, Sanofi/Regeneron, Allakos, and Lucid; received grant support from Arena, Shire/Takeda, Ellodi, Celgene/BMS, Sanofi/Regeneron, Allakos, and Lucid; and served on the data safety and monitoring board for Revolo. Adam T. Fox is President of British Society of Allergy and Clinical Immunology and Chair of Health Advisory Board of Allergy UK, which both receive commercial sponsorship. Thomas Greuter has received consulting/speaker fees from AbbVie, Norgine, Pfizer, Takeda, Dr. Falk Pharma, and Janssen; received travel grants from Vifor Pharma; and received an unrestricted research grant from the Novartis Foundation for Biomedical Research. Sandeep K. Gupta has served as a consultant for Abbott, Adare, Allakos, Celgene, Gossamer Bio, QOL, UpToDate, Medscape, and Viaskin; and received research support from Shire, Allakos, and Adare. Ikuo Hirano has received consulting fees from Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Celgene/Receptos/BMS, Eli Lilly, Eso-Cap, Gossamer Bio, Parexel/Calyx, Phathom, Regeneron, Sanofi, and Shire/Takeda; and research funding Adare/Ellodi, Allakos, Arena, AstraZeneca, Meritage, Celgene/Receptos/BMS, Regeneron/Sanofi, and Shire/Takeda.

Jennifer L. Horsley-Silva has received research funding (clinical trial site) for Regeneron/Sanofi, Allakos, Celgene, and Bristol-Myers Squibb; and served on the advisory board for Sanofi Genzyme. Shunji Ishihara has received scholarship donations from Nippon Kayaku, JIMRO, EA Pharma, KYORIN Pharmaceutical, Zeria Pharmaceutical, Mitsubishi Tanabe Pharma Corporation and Mochida Pharmaceutical, Eisai, and Otsuka Pharmaceutical; and lecture fees from AbbVie GK, Takeda Pharmaceutical, JIMRO, EA Pharma, KYORIN Pharmaceutical, Zeria Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical, Daiichi Sankyo, Janssen Pharmaceutical K.K., OLYMPUS, Otsuka Pharmaceutical, AstraZeneca plc, Chugai Pharmaceutical, and Zeon Medical Inc. Norihisa Ishimura has received lecture fees from Takeda Pharmaceutical and Otsuka Pharmaceutical; and research grant support from AstraZeneca. David A. Katzka has received research funding and consulting fees from Takeda and Regeneron. Sibylle Koletzko has received consulting/speaker fees from AbbVie, Biocodex, Danone, Janssen, Nestlé Nutrition, Pharmacosmos, Mead Johnson, Menarini, Shire, Takeda, Thermo Fisher, and Vifor. Chris A. Liacouras has served as a consultant for Abbott, Ellodi, and AstraZeneca; and as a speaker for Abbott. Alfredo J. Lucendo has received research funding from Adare/Ellodi, Dr. Falk Pharma, and Regeneron; and served as a consultant for Dr. Falk Pharma and EsoCap. Emily C. McGowan has received research funding from Regeneron. Fouad J. Moawad has served as a consultant and on the advisory board for Takeda and Sanofi/Regeneron. Vincent A. Mukkada has served as a consultant for Shire/Takeda, Allakos, and Sanofi/Genzyme; and on the adjudication board for Alladapt. Quan M. Nhu has received advisory board consulting fees from Takeda and Sanofi Genzyme. Samuel Nurko has served as a consultant for IHS. Salvatore Oliva has received advisory and speaker fees from Medtronic. Rok Orel has served as a consultant and/or speaker for Nutricia, BioGaia, Medis, AbbVie, Lek, and Dr. Falk Pharma. Alexandra Papadopoulou has received research funding from AbbVie, United Pharmaceuticals, Dr. Falk Pharma, Takeda, and AstraZeneca; served on the advisory board for Adare Pharmaceuticals, Dr. Falk Pharma, and Specialty Therapeutics; and received consulting honoraria for lectures from Uni-Pharma Pharmaceuticals, Nestlé, Cross, and Petsiavas. Robert D. Pesek has served as a consultant for Takeda. Kathryn A. Peterson has received consulting fees from Alladapt, AstraZeneca, Allakos, Bristol Meyers Squibb, Ellodi, Lucid, Takeda, Regeneron, and Medscape; has received speaker fees from Takeda, Peerview, and Regeneron; and owns equity in NexEos Bio. Hamish Philpott has served as a consultant for Dr. Falk Pharma and Arena Pharmaceuticals. Rachel Rosen has served as a consultant for Janssen Pharmaceuticals. Ekaterina Safroneeva has received consulting or speaker fees from Alimentiv, AVIR Pharma, and Sanofi-Aventis Deutschland. Philipp Schreiner has received consulting fees from Pfizer, Takeda, and Janssen-Cilag; and travel support from Falk, UCB, and Pfizer. Shauna R. Schroeder has received research funding from Regeneron and Allakos. Neil Shah is the Chief Medical Officer for Nutrition at Reckitt Healthcare. Rhonda F. Souza has received research funding from Sanofi and Phathom Pharmaceuticals; and served as a consultant for Cernostics, Phathom Pharmaceuticals, Interpace Diagnostics, Ironwood Pharmaceuticals, ISOThrive, CDx Diagnostics, Eli Lilly, and AstraZeneca. Stuart J. Spechler has served as a consultant for Phathom Pharmaceuticals, Ironwood Pharmaceuticals, Takeda Pharmaceuticals, Interpace Diagnostics, Cernostics, and ISOThrive. Alex Straumann has served as a consultant for AstraZeneca, EsoCap, Falk Pharma International, Receptos-Celgene, Regeneron-Sanofi, and Shire. Nicholas J. Talley has received nonfinancial support from HVN National Science Challenge NZ; personal fees from Aviro Health (digestive health) (2019), Anantara Life Sciences (2019), Allakos (gastric eosinophilic disease) (2021), Bayer [IBS] (2020), Danone (probiotic) (2018), Planet Innovation (gas capsule IBS) (2020), Takeda Japan (gastroparesis) (2019), twoXAR (2019) (irritable bowel syndrome drugs), Viscera Labs (2021) (irritable bowel syndrome with diarrhea), Dr. Falk Pharma (2020) (eosinophilic esophagitis), Censa (2019) (diabetic gastroparesis), Cadiila PharmIncaceuticals (CME) (2019), Progenity

Inc. (2019) (intestinal capsule), Sanofi Aventis (2019) (Probiotic), Glutagen (2020) (celiac disease), ARENA Pharmaceuticals (2019) (abdominal pain), IsoThrive (2021) (esophageal microbiome), BluMaiden (2021), Rose Pharma (2021), and Intrinsic Medicine (2021) outside the submitted work; was awarded a patent for the Nepean Dyspepsia Index (NDI) 1998, has had Biomarkers of IBS licensed, has a patent for Licensing Questionnaires of the Talley Bowel Disease Questionnaire licensed to Mayo/Talley, has a patent for Nestec (European Patent licensed), has a Singapore Provisional Patent ("Microbiota Modulation Of BDNF Tissue Repair Pathway"), and has an Australian Provisional Patent ("Diagnostic marker for functional gastrointestinal disorders"; application 2021901692); has served on committees for OzSage, the Australian Medical Council, Australian Telehealth Integration Programme, MBS Review Taskforce, the National Health and Medical Research Council (Principal Committee (Research Committee)), and the Asia Pacific Association of Medical Journal Editors; has served on the board for GESA, Sax Institute, and the Committees of the Presidents of Medical Colleges; has served on the advisory board for the International Foundation for Functional GI Disorders and AusEE; has served as a judge for the Avant Foundation (judging of research grants); has worked in Editorial for *Medical Journal of Australia* (Editor in Chief), *Up to Date* (Section Editor), *Precision and Future Medicine* (Sungkyunkwan University School of Medicine, South Korea), and *Med* (Journal of Cell Press); nad has received funding from the NHMRC to the Centre for Research Excellence in Digestive Health; and has received grant support from the NHMRC. Nikhil Thapar has received consulting and speaker fees from Takeda and Danone/Nutricia. Ulrike von Arnim has received speaker and/or consulting fees from EsoCap, AbbVie, Galapagos, Takeda, Dr. Falk Foundation, Regeneron/Sanofi, Vifor, Amgen, and Janssen. Joshua B. Wechsler has received consulting fees from Regeneron, Allakos, AstraZeneca, Sanofi, and InvenAI; and clinical trial funding from Regeneron and Allakos. Barry K. Wershil has served as a speaker for Mead Johnson Nutritionals and Abbott Nutrition. Benjamin L. Wright has received research funding from Allakos. Noam Zevit has received advisory fees from Adare Pharmaceuticals and Dr. Falk Pharma; and speaker fees from Rafa and Sanofi. Marc E. Rothenberg has served as a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, Celgene, AstraZeneca, Adare/Ellodi Pharma, GlaxoSmith Kline, Regeneron/Sanofi, Revolo Biotherapeutics, and Guidepoint; and has an equity interest in m One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex; has received royalties from reslizumab (Teva Pharmaceuticals), PEESV2 (Mapi Research Trust), and UpToDate; and is an inventor of patents owned by Cincinnati Children's Hospital. Glenn T. Furuta is the founder of EnteroTrack; and has received research funding from Holoclara, Arena, and the National Institutes of Health. Seema S. Aceves is co-inventor of oral viscous budesonide, which is UCSD patented and Takeda licensed; and has served as a consultant for Regeneron and AstraZeneca. The remaining authors disclose no conflicts.

#### Funding

The Consortium of Eosinophilic Gastrointestinal Disease Researches (CEGIR) (U54 A1117804) is part of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research, NCATS, and is funded through collaboration between National Institute of Allergy and Infectious Diseases, United States, National Institute on Diabetes and Digestive and Kidney Diseases, and National Center for Advancing Translational Sciences, United States. CEGIR is also supported by patient advocacy groups including American Partnership for Eosinophilic Disorders, United States, Campaign Urging Research for Eosinophilic Diseases, United States, and Eosinophilic Family Coalition. As a member of the Rare Disease Clinical Research Network, CEGIR is also supported by its Data Management and Coordinating Center (U2CTR002818).

**Supplementary Table 1.** Agreement Data From Round 1 of the Delphi Voting Process (n = 85)

The umbrella term for disorders of GI tract eosinophilic inflammation in the absence of secondary causes should be “eosinophilic gastrointestinal disease” (EGID)	
Strongly agree	58 (68)
Agree	24 (28)
Neither agree nor disagree	1 (1)
Disagree	1 (1)
Strongly disagree	1 (1)
When an EGID involves only the esophagus, the name should remain “eosinophilic esophagitis” (EoE)	
Strongly agree	69 (81)
Agree	14 (16)
Neither agree nor disagree	0 (0)
Disagree	1 (1)
Strongly disagree	1 (1)
When an EGID involves only the stomach, the name should be “eosinophilic gastritis”	
Strongly agree	56 (66)
Agree	25 (19)
Neither agree nor disagree	1 (1)
Disagree	2 (2)
Strongly disagree	1 (1)
The abbreviation for eosinophilic gastritis should be “EG”	
Strongly agree	44 (52)
Agree	29 (25)
Neither agree nor disagree	6 (6)
Disagree	5 (6)
Strongly disagree	0 (0)
When an EGID involves only the colon, the name should be “eosinophilic colitis”	
Strongly agree	55 (65)
Agree	25 (30)
Neither agree nor disagree	2 (2)
Disagree	1 (1)
Strongly disagree	1 (1)
The abbreviation for eosinophilic colitis should be “EC”	
Strongly agree	43 (51)
Agree	30 (35)
Neither agree nor disagree	8 (9)
Disagree	4 (5)
Strongly disagree	0 (0)
When an EGID involves the small intestine, the name should reflect the area(s) of involvement	
Strongly agree	26 (31)
Agree	31 (37)
Neither agree nor disagree	17 (20)
Disagree	10 (12)
Strongly disagree	1 (1)
When an EGID involves only the duodenum, the name should be “eosinophilic duodenitis”	
Strongly agree	30 (35)
Agree	24 (40)
Neither agree nor disagree	9 (11)
Disagree	12 (14)
Strongly disagree	0 (0)
The abbreviation for eosinophilic duodenitis should be “EoD”	
Strongly agree	28 (33)
Agree	30 (36)
Neither agree nor disagree	18 (21)
Disagree	9 (11)
Strongly disagree	0 (0)
When an EGID involves only the jejunum, the name should be “eosinophilic jejunitis”	
Strongly agree	27 (32)
Agree	27 (33)
Neither agree nor disagree	17 (20)
Disagree	13 (0)
Strongly disagree	0 (0)

**Supplementary Table 1.** Continued

The abbreviation for eosinophilic jejunitis should be “EoJ”	
Strongly agree	24 (28)
Agree	30 (36)
Neither agree nor disagree	20 (24)
Disagree	11 (13)
Strongly disagree	0 (0)
When an EGID involves only the ileum, the name should be “eosinophilic ileitis”	
Strongly agree	30 (35)
Agree	29 (35)
Neither agree nor disagree	14 (17)
Disagree	12 (14)
Strongly disagree	0 (0)
The abbreviation for eosinophilic ileitis should be “EoI”	
Strongly agree	23 (28)
Agree	29 (35)
Neither agree nor disagree	17 (21)
Disagree	14 (17)
Strongly disagree	0 (0)
When an EGID is known to involve the entire small intestine, but only the small intestine, the name should be “eosinophilic pan-enteritis”	
Strongly agree	24 (29)
Agree	26 (32)
Neither agree nor disagree	15 (19)
Disagree	16 (20)
Strongly disagree	1 (1)
The abbreviation for eosinophilic pan-enteritis should be “EN”	
Strongly agree	5 (6)
Agree	15 (18)
Neither agree nor disagree	23 (28)
Disagree	32 (39)
Strongly disagree	9 (11)
The term “eosinophilic gastroenteritis” should be removed from the EGID nomenclature system	
Strongly agree	8 (10)
Agree	21 (25)
Neither agree nor disagree	21 (25)
Disagree	25 (30)
Strongly disagree	9 (11)
For EGIDs that involve the stomach and/or small bowel and/or the colon, and ALSO the esophagus, the term EoE should NOT be used	
Strongly agree	29 (34)
Agree	32 (38)
Neither agree nor disagree	10 (12)
Disagree	11 (13)
Strongly disagree	3 (4)
For EGIDs that involve the stomach and/or small bowel and/or the colon, and ALSO the esophagus, the term to indicate this should be “with esophageal involvement”	
Strongly agree	21 (25)
Agree	42 (49)
Neither agree nor disagree	10 (12)
Disagree	10 (12)
Strongly disagree	2 (2)
When more than two GI tract areas (outside of the esophagus) are involved, the name should reflect the involved areas (ie stomach + duodenum = eosinophilic gastritis and duodenitis; duodenum + colon = eosinophilic duodenitis and colitis; etc)	
Strongly agree	22 (26)
Agree	43 (51)
Neither agree nor disagree	11 (13)
Disagree	8 (9)
Strongly disagree	1 (1)

**Supplementary Table 1.** Continued

Eosinophilic gastritis can also be called “Gastric EGID” as a synonym	
Strongly agree	7 (8)
Agree	37 (44)
Neither agree nor disagree	13 (15)
Disagree	23 (27)
Strongly disagree	5 (6)
Eosinophilic duodenitis can also be called “Duodenal EGID” as a synonym	
Strongly agree	7 (8)
Agree	32 (38)
Neither agree nor disagree	17 (20)
Disagree	24 (28)
Strongly disagree	5 (6)
Eosinophilic jejunitis can also be called “Jejunal EGID” as a synonym	
Strongly agree	7 (8)
Agree	31 (36)
Neither agree nor disagree	18 (21)
Disagree	24 (28)
Strongly disagree	5 (6)
Eosinophilic ileitis can also be called “Ileal EGID” as a synonym	
Strongly agree	7 (8)
Agree	32 (38)
Neither agree nor disagree	17 (20)
Disagree	24 (28)
Strongly disagree	5 (6)
Eosinophilic pan-enteritis can also be called “Small bowel EGID” as a synonym	
Strongly agree	7 (8)
Agree	36 (4)
Neither agree nor disagree	15 (18)
Disagree	22 (26)
Strongly disagree	5 (6)
Eosinophilic colitis can also be called “Colonic EGID” as a synonym	
Strongly agree	8 (9)
Agree	38 (45)
Neither agree nor disagree	12 (14)
Disagree	8 (9)
Strongly disagree	5 (6)
The GI wall layer of involvement (or if this is unknown) should be included in the EGID nomenclature system with sub-codes	
Strongly agree	15 (18)
Agree	42 (49)
Neither agree nor disagree	17 (20)
Disagree	11 (13)
Strongly disagree	0 (0)
Complications of EGIDs (for example, protein-losing enteropathy, ascites, or numerous others) should be included in the EGID nomenclature system with sub-codes	
Strongly agree	15 (18)
Agree	40 (47)
Neither agree nor disagree	18 (21)
Disagree	10 (12)
Strongly disagree	2 (2)
Any areas of the GI tract that are not investigated or have unknown involvement should be included in the EGID nomenclature system with sub-codes	
Strongly agree	10 (12)
Agree	20 (24)
Neither agree nor disagree	30 (35)
Disagree	21 (25)
Strongly disagree	4 (5)

Values are n (%).

EGID, eosinophilic gastrointestinal disease; GI, gastrointestinal.